Skip to the content
Know your tech before you buy it. Makers: get listed from $49/mo

1910.ai Model Foundry

1910.ai

  • Web
5.8 Club score Visit 1910.ai

What the maker publishes

Access model
The site presents the platform through flexible partnering models; Model Foundry software-module access via PaaS is listed as in development. source
Cloud and compute
ITO is described as cloud-based on Microsoft Azure, with Azure Quantum Elements and Microsoft and NVIDIA partnerships for multi-GPU compute. source
Data orchestration
Data Orchestration formats, analyzes, cleans, annotates, curates, and featurizes multimodal data before model ingestion. source
Federated learning
Federated learning supports collaborative training across blinded datasets from multiple companies without sharing the datasets themselves. source
Headquarters
Boston Seaport source
Maker history
1910 says it was founded in 2018 and is headquartered in Cambridge, Massachusetts. source
Model capabilities
The platform includes model evaluation, selection, sampling, training, inference, observability, molecule provenance, alignment, and safety. source
Model Foundry
Model Foundry includes hundreds of AI/ML models and a Multi-AI Agent System for drug-discovery optimization. source
Molecule design
After data ingestion, the platform produces an in-silico molecule and suggests synthetic routes to support feasibility, yield, and scale-up. source
Partner audience
Partnering models are presented for pharma, biotech, venture capital and lab incubators, academia, and government. source
Privacy approach
The site says private data remains on local devices or partners' data centers in its federated-learning workflow. source
Product purpose
ITO integrates multimodal data, AI models, and lab automation to support small- and large-molecule drug discovery. source
Supported modalities
The platform lists small molecules, peptides, and biologics as modalities for federated learning. source
Target identification
AI-driven Precision Target ID uses multiomic patient-derived tissue and clinical data to identify novel biological targets. source

Checked against the maker's pages on 14 Nov 2026.